|
11 |
How Do We Manage Hematopoietic Cell Transplant during the SARS-CoV-2 Pandemic?
Enthalten in Acta haematologica Bd. 144, 2021, Nr. 5: 500-507. 8 S.
|
|
|
|
12 |
G-CSF and GM-CSF Are Different. Which One Is Better for COVID-19?
Enthalten in Acta haematologica Bd. 144, 2021, Nr. 4: 355-359. 5 S.
|
|
|
|
13 |
Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF?
Enthalten in Acta haematologica Bd. 144, 2021, Nr. 3: 350-351. 2 S.
|
|
|
|
14 |
Perspective: SARS-CoV-2, COVID-19 and Haematologists
Enthalten in Acta haematologica Bd. 144, 2021, Nr. 2: 117-121. 5 S.
|
|
|
|
15 |
A Haematologist’s Guide to Coronavirus Disease 2019: Encyclopaedia or Doorstop?
Enthalten in Acta haematologica Bd. 144, 2021, Nr. 1: 8-9
|
|
|
|
16 |
The paradox of haematopoietic cell transplant in Latin America
Enthalten in Bone marrow transplantation 13.5.2021: 1-7
|
|
|
|
17 |
Economics influences therapy decisions in chronic myeloid leukaemia: should it?
Enthalten in Journal of cancer research and clinical oncology 22.4.2021: 1-6
|
|
|
|
18 |
Impact of socio-demographic co-variates on prognosis, tyrosine kinase-inhibitor use and outcomes in persons with newly-diagnosed chronic myeloid leukaemia
Enthalten in Journal of cancer research and clinical oncology 9.4.2021: 1-11
|
|
|
|
19 |
High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia
Enthalten in Leukemia 22.1.2021: 1-4
|
|
|
|
20 |
Treating Plasma Cell Myeloma in Developing Countries: Does Everyone Need the Newest Drugs?
Enthalten in Acta haematologica Bd. 143, 2020, Nr. 6: 513-515
|
|
Administration
